Based on this YouTube video's total view count of 53.1K views and industry-standard rates, the estimated total earning is $37 - $106 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore A CEO Finished His Morning Workout. 2 Weeks Later, His Spine Was Fused With Titanium. with 53,143 views, 1,943 likes, and 168 comments. Experience the impact of this video content that has captured audience attention.

Sid Sijbrandij felt a sharp pain during a bench press. An emergency room X-ray showed nothing, but weeks later, the terrifying truth was revealed: a six-centimeter tumor was growing directly from his spine. He was a forty-five-year-old billionaire, the co-founder of GitLab, and the cancer growing inside him was an adolescent disease that standard medicine had not figured out how to cure since the 1980s. This episode reveals the terrifying reality of osteosarcoma in adults, how a routine gym injury masked a lethal bone cancer, and the unprecedented interventions one man forced into existence, including a biological AND-gate CAR-T cell, when the medical system told him he had simply run out of options. ⚠️ Don't let the system fail you. Subscribe to Diagnosis Glitch for weekly medical mysteries exposed: https://www.youtube.com/@Diagnosis_Glitch?sub_confirmation=1 - - - 💀 THE FATAL ERRORS: - The Diagnostic Delay: How a six-centimeter malignant tumor was entirely missed by a standard emergency room X-ray and later terrifyingly misdiagnosed as an aortic aneurysm. - The Age Exclusion: How clinical trials for osteosarcoma are built almost exclusively for pediatric populations, effectively locking adult terminal patients out of experimental treatments. - The Treatment Ceiling: How the medical establishment offered a standard 1980s chemotherapy protocol that destroyed his body, and upon recurrence, simply wished him "good luck." - The False Positive Match: How seven separate doctors reviewed a lung scan and confidently diagnosed terminal metastatic spread, a lethal error overturned by only one dissenting voice. - The Financial Abandonment: How pharmaceutical companies have abandoned highly effective MDM2 inhibitors simply because the patient pool isn't large enough to guarantee a profitable shareholder return. ⏱️ TIME OF DEATH: 00:00 - Intro: The Bench Press Pain 01:31 - The ER: "You Might Have An Aneurysm" 02:15 - Sid Sijbrandij: Founder Mode 03:42 - The Six-Centimeter Anomaly 04:55 - The 1980s Protocol: Standard of Care 06:12 - Mid-2024: The Local Recurrence 07:30 - The Age Exclusion: Locked Out of Trials 08:44 - The AI Discovery: Fibroblast Activation Protein 10:02 - Five Treatments In Parallel 11:25 - The Radioligand Therapy 12:18 - The Dual AND-Gate CAR-T Cell 13:58 - The Near-Miss: Seven Doctors Were Wrong 15:10 - The Real Glitch: Access vs. Science 16:45 - What You Need To Know 18:15 - The System Did Not Break. The Wall Did. - - - ❓ PATIENT HISTORY: Osteosarcoma is the most common primary malignant bone tumor, but in adults, it is extraordinarily rare. Because of strict inclusion criteria in clinical trials, adult patients facing recurrence are often locked out of therapies that could save their lives. Sid's story exposes the massive gulf between the science that exists and the patients who are allowed to access it. Does knowing that life-saving cancer drugs sit abandoned in freezers because they are not profitable enough change how you look at the medical system? Let us know in the comments. 👋 ABOUT DIAGNOSIS GLITCH: We explore the edge cases where medicine fails. The misdiagnoses, the anomalies, and the system errors that cost lives. When the body glitches, we find the code. ⚖️ LEGAL & PRIVACY: This story is based on documented events. All names are real. This case explores the diagnosis and ongoing treatment of Sid Sijbrandij as of early 2026. AI was used to alter the footage in this video. This content is intended for awareness, research, and educational purposes. Osteosarcoma in older adults is rare, and older patients are frequently excluded from pediatric-focused clinical trials due to age constraints. The FDA expanded access (compassionate use) pathway exists but requires significant resources to navigate rapidly. The personalized treatments discussed, including FAP radioligand therapy, custom mRNA cancer vaccines, SQ3370 click chemistry, and dual AND-gate CAR-T cells, are experimental therapies developed under specific clinical exemptions. The statements regarding clinical trial constraints, FDA single-patient IND applications, and pharmaceutical drug abandonment reflect systemic issues in drug development. This video is for educational and entertainment purposes only and does not constitute medical advice.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.